Bone Marrow Transplantation in refractory oral cGVHD. Our patient had experienced significant pain and weight loss as a result of the oral lesions that progressed despite oral steroid and cyclosporin rinses and systemic tacrolimus, mycophenolate mofetil, and ursodeoxycholic acid. The intraoral PUVA therapy was easily accomplished in an outpatient setting using standard dental equipment available in most community settings.
Successful use of intraoral PUVA treatment for oral cGVHD in two patients was first reported by Atkinson in 1986 . 1 Since then, rare reports of intraoral PUVA use have appeared. At Johns Hopkins, over a 14-year period, seven patients were treated with a hand-held UVA light source using a glass fiber extension (National Biologic Corporation, Ohio USA). Applications of 0.5 J/cm 2 and increased by 0.5 J/cm 2 as tolerated two to four times/week, for an average of 26 treatments, resulted in four complete responses, two partial responses, and one response upon the addition of topical steroids. 2 Using an outdated Nuvalight activator light (Caulk Inc) used in the 1970s to cure dental sealant, a patient with refractory oral cGVHD achieved a response with 17 treatments. 3 Intraoral ultraviolet B irradiation (without psoralen) 0.02 mJ/cm 2 two to three times/week (dose escalated by 0.02 mJ/cm 2 every fourth session) was also effective in two patients with cGVHD lesions. 4 Several mechanisms of action of PUVA therapy may be responsible for its effectiveness in cGVHD. 5 Eight-methoxyopsoralen rapidly diffuses into nucleated cells and upon exposure to UVA irradiation covalently binds DNA thereby inhibiting proliferation and mitosis, and causing rapid induction of apoptosis of activated T cells. 6, 7 Treated monocytes exhibit an activated phenotype with increased phagocytic and antigen presenting activity facilitating processing of apoptotic T cells leading to induction of anticlonotypic immunity. PUVA causes alterations in the idotypes expressed by clones of autoreactive T cells through upregulaton of class I expression triggering the induction of specific autoregulatory T cells, most likely CD8 with suppressive or cytoxic capabilities. 8, 9 PUVA also interferes with the function of Langerhans cells, including antigen processing
Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation
Lymphoproliferative disorder after bone marrow transplantation (BMT) usually occurs in lymph nodes of the pharynx, mediastinum and retroperitoneum. We describe three patients who developed post-transplant lymphoproliferative disorder (PTLD) presenting as pulmonary nodules. Epstein-Barr virus (EBV)-associated lymphoproliferative disorder is a potentially fatal complication of BMT. Acquired immunodeficiency after BMT results in impaired T cell immunity, which contributes to expansion of B cells infected with EBV. Risk factors for BMT-associated PTLD include HLA mismatch, T cell depletion, donor cytomegaand IL-1 production, reduction of T lymphocyte responses, and decreases in IL-2 and IL-1 production. Patient 1: A 14-month-old female with acute myeloid leukemia (FAB: M4) received a HLA A-mismatched, Band DRB1-matched, unrelated donor BMT in first complete remission. She received cyclophosphamide 120 mg/kg i.v., total body irradiation (TBI) 1320 cGy, and GVHD prophylaxis consisting of methotrexate 15 mg/m 2 i.v. on day 1 and 10 mg/m 2 i.v. daily on days +3, +6 and +11 after BMT. She achieved full donor chimerism with no GVHD. She received no ATG and both recipient and donor were CMVnegative. Three months after BMT she complained of cough. A CT scan showed a right middle lobe pleural-based nodule (Figure 1 ). An open lung biopsy 85 days after BMT showed a B-lineage PTLD, monomorphic, diffuse large cell-type. Immunophenotyping revealed monoclonal surface expression of IgG-kappa in conjunction with HLA- , without response. He developed multiorgan failure and support was withdrawn on day +241 after BMT. An autopsy showed bilateral large cell lymphoma involving all lobes of the lungs and occupying about 50% of the total lung volume. There was no evidence of lymphoma outside the lungs, including the bone marrrow.
Patient 3: A 15-month-old female with dysostosis multiplex was diagnosed with I-cell disease (mucolipidosis type II). At 18 months of age, she received an HLA-matched elutriated sibling BMT, after conditioning with cyclophosphamide 120 mg/kg i.v. and TBI 1400 cGy. She received ATG 15 mg/kg/dose i.v. twice a day on days −3, −2, and −1 before BMT (total dose 90 mg/kg). GVHD prophylaxis consisted of methylprednisolone and cyclosporin A. Donor and recipient were CMV-positive. She achieved full donor chimerism. She developed recurrent fevers 9 months after BMT. CT scans revealed a right basilar pulmonary nodule (Figure 3a) and multiple hypodense regions in the liver (Figure 3b) . A liver biopsy on day +346 after BMT showed a B-lineage PTLD, monomorphic, diffuse large cell-type. Immunophenotyping demonstrated monoclonal expression of IgM-kappa, HLA-DR, CD45, CD20 and CD22. Southern blot analysis showed clonal EBV. She was treated with one dose of cyclophosphamide 600 mg/m 2 i.v. and three doses of DLI (1 × 10 6 CD3-positive cells/kg), after which she developed clinical grade 2 GVHD of both her skin and gastrointestinal tract. She had complete resolution of the pulmonary nodule and liver lesions. She remains well 3 years after the diagnosis of lymphoma.
We report three cases of high-grade PTLD presenting as pulmonary parenchymal lesions in patients after allogeneic BMT. Histopathologic evaluation of biopsy specimens with immunophenotyping, EBV PCR, and EBV clonality assessment by Southern blotting define these EBV-driven malignancies. 3 Although not routine, in the immunocompromised host, EBV viral load testing by quantitative DNA amplification is more reliable than EBV serology as an early marker of lymphoproliferation and potentially useful for monitoring therapy response in PTLD patients. 4 The reduction of immunosuppressive medications may cure some anatomically limited lymphoproliferative lesions. 5 Unmanipulated donor-derived lymphocyte infusions and anti-CD20 monoclonal antibody rituximab have also been used to treat EBV-associated PTLD. 6 In patients who do not respond to these therapies, durable complete responses have been achieved with chemotherapy. Adoptive transfer of EBV-specific cytotoxic T cells has been effective in selected patients. 7 In our patients, we observed durable remissions in two patients treated with DLI alone or with DLI and chemotherapy. In the third patient, the lymphoma progressed despite aggressive chemotherapy, illustrating the variable clinical behavior of these malignancies. In summary, these cases demonstrate that consideration of PTLD in the differential diagnosis of pulmonary nodules is important, since PTLD is a potentially treatable complication of BMT. As both lower respiratory infection and PTLD can result from immunosuppression after BMT and both can present with fever and cough, early diagnosis can be difficult. The cases we present indicate the need for early aggressive strategies to diagnose patients with pulmonary nodules of unclear etiology. Laboratory Medicine and SM Davies
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